Annotation Detail

Information
Associated Genes
ABL1
Associated Variants
ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L)
Associated Disease
chronic myeloid leukemia
Source Database
CIViC Evidence
Description
In a study of 39 chronic phase CML patients with BCR-ABL variants, F317L was seen in 8 imatinib resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/6978
Gene URL
https://civic.genome.wustl.edu/links/genes/4
Variant URL
https://civic.genome.wustl.edu/links/variants/241
Rating
3
Evidence Type
Predictive
Disease
Chronic Myeloid Leukemia
Evidence Direction
Supports
Drug
Imatinib Mesylate
Evidence Level
C
Clinical Significance
Resistance
Pubmed
22371878
Drugs
Drug NameSensitivitySupported
Imatinib MesylateResitance or Non-Reponsetrue